LianBio Enters Into Agreement With Janssen Pharmaceutical, Assigns NBTXR3 Rights In China And Other Asian Markets For $25M

Author: Benzinga Newsdesk | December 26, 2023 03:16am

LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV ("Janssen"), a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio's exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.

Under the terms of the agreement, LianBio will receive a one-time payment of $25 million. In addition, LianBio is eligible to receive a sales milestone payment of $5 million. Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.

Posted In: JNJ LIAN